Agilent Forms Collaboration with Seoul National Hospital
Agilent Technologies (California, USA) has announced a strategic collaboration with Seoul National Hospital (Seoul, Korea). The collaboration will focus on the identification and verification of biomarkers to further the development of drugs. Under the agreement, the hospital?s department of medicine will use liquid chromatography?mass spectrometry (LC?MS) instrumentation from Agilent to further research in this area
Agilent Technologies (California, USA) has announced a strategic collaboration with Seoul National Hospital (Seoul, Korea). The collaboration will focus on the identification and verification of biomarkers to further the development of drugs. Under the agreement, the hospital’s department of medicine will use liquid chromatography–mass spectrometry (LC–MS) instrumentation from Agilent to further research in this area.
According to Professor Byung-Hee Oh, president and CEO of the hospital, there are gaps within the medical industry that limit the quality of care that can be provided to patients. He said: "One area we want to address is the development of biomarkers for early detection and effective monitoring of a range of diseases."
Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region, said: "We are privileged to partner with Seoul National University Hospital, which has a strong tradition of innovation and quality care for customers." He added: "Through this collaboration, we hope to establish more effective and varied verifications system for the medical and life sciences industries."
For more information please visit www.agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
